US Edition
Ibogaine is drawing new interest from the Trump administration. Here’s what to know about the psychedelic
The order includes a $50 million state grant program as officials weigh ibogaine and other psychedelics for opioid withdrawal, PTSD and depression.
- On Saturday, April 18, 2026, President Donald Trump signed an executive order directing federal agencies to accelerate research into ibogaine as a treatment for veterans suffering from post-traumatic stress disorder and other conditions.
- Addressing a veteran mental health crisis, more than 6,000 veterans die by suicide annually, prompting advocacy groups like Veterans Exploring Treatment Solutions to push for broader access to emerging therapies.
- Federal agencies will utilize $50 million in new funding for research, while FDA Commissioner Dr. Marty Makary announced the agency will issue National Priority Vouchers to expedite clinical trial reviews within one to two months.
- While states like Kentucky are passing legislation to study the drug, ibogaine remains a Schedule I controlled substance and illegal in the U.S., forcing many veterans to seek treatment in unregulated clinics in Mexico.
- Experts caution that ibogaine carries risks of abnormal heart rhythms and could cause vomiting, though government-sanctioned treatments could potentially begin as early as summer 2026 once rigorous safety protocols are established.
20 Articles
20 Articles
For doctor Bruno Rasmussen, US initiative can generate domino effect and drive debates in countries like Brazil, where the substance already has clinical use
Trump’s Rogan-inspired psychedelics order stokes cautious optimism
President Trump’s executive order loosening research restrictions on psychedelic medicine, which was kick-started by a text to Trump from podcaster Joe Rogan, could help legitimize an industry that’s long operated in the shadows. Advocates and researchers said they are optimistic about a potential shift in how the government views psychedelic drugs, but without further action,…
Trump signs order to accelerate Ibogaine research for veterans with PTSD
The order focuses on advancing studies of ibogaine, a Schedule I psychedelic drug, for use in treating PTSD, traumatic brain injury, depression, anxiety, suicidal ideatiation, and opiod addiction.
Mississippi prepares for ibogaine research as federal order could accelerate plans
JACKSON, Miss. (WLBT) – Mississippi is preparing for ibogaine research as a new federal executive order could accelerate plans to study the drug in the state. The push for more ibogaine research is an experience veteran Myles Grantham has lived. He traveled to Mexico in 2019 to get ibogaine after years of injuries, migraines and depression following multiple deployments. “We shouldn’t have to go to Mexico to get this type of treatment,” Grantham…
President Donald Trump signed an executive order on Saturday, April 18 that seeks to accelerate research and access to psychedelic drugs as a treatment for serious mental illness, including treatment-resistant depression and post-traumatic stress disorder (PTSD).The order allocates $50 million in federal funds to equalize state investments and orders the FDA to accelerate the review of substances such as psilocybin and ibogain, according to NPR.…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
